BACKGROUND: Reducing nebulisation times for tobramycin solution for inhalation in cystic fibrosis (CF) may improve compliance. METHODS: In this single-dose, open-label, two-way crossover study, 13 subjects (7 CF, 6 healthy) were randomised to receive tobramycin via eFlow rapid or LC Plus jet nebuliser. Drug deposition in the lung using gamma scintigraphic imaging, nebulisation times, pharmacokinetics, and safety were evaluated. RESULTS: In CF patients, whole-lung deposition was 40% less with the eFlow rapid compared with LC Plus nebulisers was (8.9±0.8%, and 15.1±6.0%, p>0.05). Nebulisation time was shorter with eFlow rapid compared to LC Plus (7.0min versus 20.0min, p<0.05). Lung deposition in healthy subjects was comparable between both devices. CONCLUSIONS: eFlow rapid reduces the nebulisation time of tobramycin and can potentially improved compliance in patients with CF. Copyright Â
RCT Entities:
BACKGROUND: Reducing nebulisation times for tobramycin solution for inhalation in cystic fibrosis (CF) may improve compliance. METHODS: In this single-dose, open-label, two-way crossover study, 13 subjects (7 CF, 6 healthy) were randomised to receive tobramycin via eFlow rapid or LC Plus jet nebuliser. Drug deposition in the lung using gamma scintigraphic imaging, nebulisation times, pharmacokinetics, and safety were evaluated. RESULTS: In CF patients, whole-lung deposition was 40% less with the eFlow rapid compared with LC Plus nebulisers was (8.9±0.8%, and 15.1±6.0%, p>0.05). Nebulisation time was shorter with eFlow rapid compared to LC Plus (7.0min versus 20.0min, p<0.05). Lung deposition in healthy subjects was comparable between both devices. CONCLUSIONS: eFlow rapid reduces the nebulisation time of tobramycin and can potentially improved compliance in patients with CF. Copyright Â
Authors: Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin Journal: Clin Pharmacokinet Date: 2015-05 Impact factor: 6.447
Authors: Rachel Yoon Kyung Chang; Philip Chi Lip Kwok; Sussan Ghassabian; John D Brannan; Heikki O Koskela; Hak-Kim Chan Journal: Br J Pharmacol Date: 2020-08-07 Impact factor: 8.739
Authors: Aukje C Bos; Cedric van Holsbeke; Jan W de Backer; Mireille van Westreenen; Hettie M Janssens; Wim G Vos; Harm A W M Tiddens Journal: PLoS One Date: 2015-03-03 Impact factor: 3.240
Authors: Stephen Pham; Gary T Ferguson; Edward Kerwin; Thomas Goodin; Alistair Wheeler; Andrea Bauer Journal: J Aerosol Med Pulm Drug Deliv Date: 2017-11-10 Impact factor: 2.849